<i>Escherichia coli</i> producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen
This case illustrates the clinical utility of a carbapenem-sparing strategy guided by TDM in a high-risk, ARC patient with an AmpC-producing <i>E. coli</i> BSI. Continuous infusion CZA achieved pharmacokinetic/pharmacodynamic targets associated with therapeutic success, offering a promising alternative to carbapenems while mitigating the risk of resistance development and microbiota disruption.
Authors
- Robert A. Bonomo (ORCID: https://orcid.org/0000-0002-3299-894X)
- Mariagrazia Perilli (ORCID: https://orcid.org/0000-0001-7370-1455)
- Alessandra Piccirilli (ORCID: https://orcid.org/0000-0001-7560-5221)
- Renato Fanin (ORCID: https://orcid.org/0000-0003-1030-2435)
- Simone Lanini (ORCID: https://orcid.org/0000-0002-6743-4001)
- Francesca Patriarca (ORCID: https://orcid.org/0000-0002-9813-524X)
- Simone Giuliano (ORCID: https://orcid.org/0000-0003-2475-8732)
- Carlo Tascini (ORCID: https://orcid.org/0000-0001-9625-6024)
- J Angelini
- L Martini
- Tosca Semenzin
Institutions
- University of Udine (IT)
- University of L'Aquila (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- Case Western Reserve University (US)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/jacamr/dlaf109
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00